Advanced Biomed (ADVB) Return on Equity ROE from the fourth quarter 2026 to fourth quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Advanced Biomed Inc.  (Nasdaq: ADVB)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Advanced Biomed's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Advanced Biomed in the fourth quarter 2026?
Advanced Biomed Inc. achieved a return on average equity (ROE) of 102.12 % in its fourth quarter 2026, which is below Advanced Biomed's average return on equity, which stands at 122.25%.

ROE fell compared to the third quarter 2026, despite the net income growth of % from the third quarter 2026.

Within the Medical Laboratories industry Advanced Biomed Inc. achieved the highest return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2026 from 57 to 71.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
IV. Quarter		 (Mar 31 2026)
III. Quarter		 (Dec 31 2025)
II. Quarter		 (Sep 30 2025)
I. Quarter		 (Jun 30 2025)
IV. Quarter
Y / Y Equity Change 253.02 % 123.01 % 168.71 % 80.61 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 7 5 4 -3 -3
Return On Equity (TTM) 102.12 % 121.71 % 142.91 % -120.4 % -131.81 %
ADVB's Total Ranking # 71 # 57 # # #
Equity (TTM) in Millions 12 9 2 3 3
Seq. Equity Change 33.3 % 453.7 % -44.63 % -13.62 % -15.79 %
Seq. Net Income Change - - - - -

Back to ADVB Management Effectiveness >> ADVB's 5 Years Annual ROE >> Compare ADVB ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall # 71

Return On Equity Statistics
High Average Low
142.91 %
122.25 %
102.12 %
(Dec 31 2025)   (Jun 30 2026)





ADVB Annual Return On Equity (Jun 30 2026)
2026		 (Jun 30 2024)
2025


Total Equity in Millions 12 2 0 0 0
Y / Y Equity Change 638.09 % - - - -
Net Income in Millions 7 -3 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity 54.39 % -167.28 % - - -

Back to ADVB Management Effectiveness >> ADVB's 5 Years Annual ROE >> Compare ADVB ROE to its Competitors




Annual Roe Comment
In 2026 ROE improved to 54.39 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ADVB's' Return on Equity at Yahoo Finance
ADVB's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ADVB's Competitors
Subscribers only: Roe for Advanced Biomed's Suppliers
Subscribers only: Return On Equity for ADVB's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Silexion Therapeutics Corp  276.59 %
Actinium Pharmaceuticals Inc  213.46 %
Halozyme Therapeutics Inc   180.63 %
Capforce Inc   168.50 %
Aveanna Healthcare Holdings Inc   150.35 %
Liquidia Corporation  149.64 %
Interpace Biosciences Inc   142.98 %
Oncotelic Therapeutics Inc   124.17 %
Fortress Biotech Inc   118.22 %
Medpace Holdings Inc   110.15 %
Advanced Biomed Inc.  102.12 %
Rigel Pharmaceuticals Inc  96.49 %
Exelixis Inc   93.62 %
Alnylam Pharmaceuticals Inc   93.61 %
Eli Lilly And Company  92.54 %
Arbutus Biopharma Corp  90.98 %
Amgen Inc   89.32 %
Escalon Medical Corp   82.47 %
Q32 Bio Inc   76.88 %
3m Company  76.55 %
Oramed Pharmaceuticals Inc  73.03 %
Tg Therapeutics Inc   72.30 %
Idexx Laboratories Inc  71.96 %
Elite Pharmaceuticals Inc   71.10 %
Zoetis Inc   68.87 %
Rallybio Corporation  68.56 %
Earth Science Tech Inc   66.17 %
Aurinia Pharmaceuticals Inc   59.00 %
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %

Date modified: 2026-10-14T16:54:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.